Clinical features and outcomes of COVID-19 patients with benign
prostatic hyperplasia in aging male: A retrospective study of 18 cases
Abstract
Aim: A worldwide pandemic of coronavirus disease 2019 (COVID-19) which
emerged in China in December 2019 affects the world very seriously. We
aimed to evaluate the benign prostatic hyperplasia (BPH) patients who
were admitted and treated to our hospital due to COVID-19. Methods:
Between March 18, 2020 and April 5, 2020 , 18 patients admitted with
COVID-19 who has BPH and are using medication for this were included in
the study and analyzed retrospectively. Diagnosis was confirmed by
COVID-19 nucleic acid test by sampling sputum or nasopharyngeal swab.
Standard COVID-19 treatment protocol determined by our Ministry of
Health was applied to all patients according to their risk groups.
Epidemiological, clinical, radiological features, additional diseases,
laboratory tests, complications and outcome data of all patients were
recorded. Results: Mean age of patients was 59.6 (range: 56-73). As the
mode of transmission, 10 (55.5%) of patients were infected in hospital,
5 (27.7%) patients had a relative with COVID-19 and 3 (16,6%) was
unknown. During follow-up, 2 (11.1%) patients were transferred to
intensive care unit (ICU). One of these patients dramatically progressed
and died. Patients who survived and were not transferred to ICU had
lesser comorbidities and were relatively young. Mean duration of
hospitalization was 14.2 days (range 12-19). Conclusion: We think that
COVID-19 patients with BPH had a low mortality rate and did not have a
poor prognosis in this patient group. It is crucial to take
comprehensive preventive measures to control COVID-19 transmission via
hospital route.